2018-2023 Global Drugs for Vulvovaginal Candidiasis Consumption Market Report

August 2018 | 131 pages | ID: 2217EEDA423EN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Drugs for Vulvovaginal Candidiasis market for 2018-2023.

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
The classification of Drugs for Vulvovaginal Candidiasis includes Cream, Pessary and other. The proportion of Cream in 2017 is about 47.2%, and the proportion of Pessary in 2017 is about 34.1%.
The drugs for Vulvovaginal Candidiasis are Miconazole, Clotrimazole, Fluconazole, Econazole and Other, market share of Fluconazole is about 24.5% in 2017.
Drugs for Vulvovaginal Candidiasis is application in Hospital & Clinic and Pharmacy. The most of Drugs for Vulvovaginal Candidiasis is used in Pharmacy, and the market share in 2016 is about 59%.
Over the next five years, LPI(LP Information) projects that Drugs for Vulvovaginal Candidiasis will register a 2.1% CAGR in terms of revenue, reach US$ 870 million by 2023, from US$ 770 million in 2017.

This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Vulvovaginal Candidiasis market by product type, application, key manufacturers and key regions.

To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:

Segmentation by product type:

• Cream
• Pessary
• Other

Segmentation by application:

• Hospital & Clinic
• Pharmacy

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Spain
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:

• Bayer
• Perrigo
• J & J
• Pfizer
• Bristol-Myers Squibb
• Effik
• Teva
• Sanofi
• Cisen Pharmaceutical
• Kingyork Group

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

• To study and analyze the global Drugs for Vulvovaginal Candidiasis consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
• To understand the structure of Drugs for Vulvovaginal Candidiasis market by identifying its various subsegments.
• Focuses on the key global Drugs for Vulvovaginal Candidiasis manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
• To analyze the Drugs for Vulvovaginal Candidiasis with respect to individual growth trends, future prospects, and their contribution to the total market.
• To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
• To project the consumption of Drugs for Vulvovaginal Candidiasis submarkets, with respect to key regions (along with their respective key countries).
• To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
• To strategically profile the key players and comprehensively analyze their growth strategies.

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Drugs for Vulvovaginal Candidiasis Consumption 2013-2023
  2.1.2 Drugs for Vulvovaginal Candidiasis Consumption CAGR by Region
2.2 Drugs for Vulvovaginal Candidiasis Segment by Type
  2.2.1 Cream
  2.2.2 Pessary
  2.2.3 Other
2.3 Drugs for Vulvovaginal Candidiasis Consumption by Type
  2.3.1 Global Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type (2013-2018)
  2.3.2 Global Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Type (2013-2018)
  2.3.3 Global Drugs for Vulvovaginal Candidiasis Sale Price by Type (2013-2018)
2.4 Drugs for Vulvovaginal Candidiasis Segment by Application
  2.4.1 Hospital & Clinic
  2.4.2 Pharmacy
2.5 Drugs for Vulvovaginal Candidiasis Consumption by Application
  2.5.1 Global Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application (2013-2018)
  2.5.2 Global Drugs for Vulvovaginal Candidiasis Value and Market Share by Application (2013-2018)
  2.5.3 Global Drugs for Vulvovaginal Candidiasis Sale Price by Application (2013-2018)

3 GLOBAL DRUGS FOR VULVOVAGINAL CANDIDIASIS BY PLAYERS

3.1 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Players
  3.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Players (2016-2018)
  3.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Players (2016-2018)
3.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Players
  3.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Players (2016-2018)
  3.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Players (2016-2018)
3.3 Global Drugs for Vulvovaginal Candidiasis Sale Price by Players
3.4 Global Drugs for Vulvovaginal Candidiasis Manufacturing Base Distribution, Sales Area, Product Types by Players
  3.4.1 Global Drugs for Vulvovaginal Candidiasis Manufacturing Base Distribution and Sales Area by Players
  3.4.2 Players Drugs for Vulvovaginal Candidiasis Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 DRUGS FOR VULVOVAGINAL CANDIDIASIS BY REGIONS

4.1 Drugs for Vulvovaginal Candidiasis by Regions
  4.1.1 Global Drugs for Vulvovaginal Candidiasis Consumption by Regions
  4.1.2 Global Drugs for Vulvovaginal Candidiasis Value by Regions
4.2 Americas Drugs for Vulvovaginal Candidiasis Consumption Growth
4.3 APAC Drugs for Vulvovaginal Candidiasis Consumption Growth
4.4 Europe Drugs for Vulvovaginal Candidiasis Consumption Growth
4.5 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Growth

5 AMERICAS

5.1 Americas Drugs for Vulvovaginal Candidiasis Consumption by Countries
  5.1.1 Americas Drugs for Vulvovaginal Candidiasis Consumption by Countries (2013-2018)
  5.1.2 Americas Drugs for Vulvovaginal Candidiasis Value by Countries (2013-2018)
5.2 Americas Drugs for Vulvovaginal Candidiasis Consumption by Type
5.3 Americas Drugs for Vulvovaginal Candidiasis Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC Drugs for Vulvovaginal Candidiasis Consumption by Countries
  6.1.1 APAC Drugs for Vulvovaginal Candidiasis Consumption by Countries (2013-2018)
  6.1.2 APAC Drugs for Vulvovaginal Candidiasis Value by Countries (2013-2018)
6.2 APAC Drugs for Vulvovaginal Candidiasis Consumption by Type
6.3 APAC Drugs for Vulvovaginal Candidiasis Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 EUROPE

7.1 Europe Drugs for Vulvovaginal Candidiasis by Countries
  7.1.1 Europe Drugs for Vulvovaginal Candidiasis Consumption by Countries (2013-2018)
  7.1.2 Europe Drugs for Vulvovaginal Candidiasis Value by Countries (2013-2018)
7.2 Europe Drugs for Vulvovaginal Candidiasis Consumption by Type
7.3 Europe Drugs for Vulvovaginal Candidiasis Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Drugs for Vulvovaginal Candidiasis by Countries
  8.1.1 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption by Countries (2013-2018)
  8.1.2 Middle East & Africa Drugs for Vulvovaginal Candidiasis Value by Countries (2013-2018)
8.2 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption by Type
8.3 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers and Impact
  9.1.1 Growing Demand from Key Regions
  9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 MARKETING, DISTRIBUTORS AND CUSTOMER

10.1 Sales Channel
  10.1.1 Direct Marketing
  10.1.2 Indirect Marketing
10.2 Drugs for Vulvovaginal Candidiasis Distributors
10.3 Drugs for Vulvovaginal Candidiasis Customer

11 GLOBAL DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FORECAST

11.1 Global Drugs for Vulvovaginal Candidiasis Consumption Forecast (2018-2023)
11.2 Global Drugs for Vulvovaginal Candidiasis Forecast by Regions
  11.2.1 Global Drugs for Vulvovaginal Candidiasis Forecast by Regions (2018-2023)
  11.2.2 Global Drugs for Vulvovaginal Candidiasis Value Forecast by Regions (2018-2023)
  11.2.3 Americas Consumption Forecast
  11.2.4 APAC Consumption Forecast
  11.2.5 Europe Consumption Forecast
  11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
  11.3.1 United States Market Forecast
  11.3.2 Canada Market Forecast
  11.3.3 Mexico Market Forecast
  11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
  11.4.1 China Market Forecast
  11.4.2 Japan Market Forecast
  11.4.3 Korea Market Forecast
  11.4.4 Southeast Asia Market Forecast
  11.4.5 India Market Forecast
  11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
  11.5.1 Germany Market Forecast
  11.5.2 France Market Forecast
  11.5.3 UK Market Forecast
  11.5.4 Italy Market Forecast
  11.5.5 Russia Market Forecast
  11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
  11.6.1 Egypt Market Forecast
  11.6.2 South Africa Market Forecast
  11.6.3 Israel Market Forecast
  11.6.4 Turkey Market Forecast
  11.6.5 GCC Countries Market Forecast
11.7 Global Drugs for Vulvovaginal Candidiasis Forecast by Type
11.8 Global Drugs for Vulvovaginal Candidiasis Forecast by Application

12 KEY PLAYERS ANALYSIS

12.1 Bayer
  12.1.1 Company Details
  12.1.2 Drugs for Vulvovaginal Candidiasis Product Offered
  12.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
  12.1.4 Main Business Overview
  12.1.5 Bayer News
12.2 Perrigo
  12.2.1 Company Details
  12.2.2 Drugs for Vulvovaginal Candidiasis Product Offered
  12.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
  12.2.4 Main Business Overview
  12.2.5 Perrigo News
12.3 J & J
  12.3.1 Company Details
  12.3.2 Drugs for Vulvovaginal Candidiasis Product Offered
  12.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
  12.3.4 Main Business Overview
  12.3.5 J & J News
12.4 Pfizer
  12.4.1 Company Details
  12.4.2 Drugs for Vulvovaginal Candidiasis Product Offered
  12.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
  12.4.4 Main Business Overview
  12.4.5 Pfizer News
12.5 Bristol-Myers Squibb
  12.5.1 Company Details
  12.5.2 Drugs for Vulvovaginal Candidiasis Product Offered
  12.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
  12.5.4 Main Business Overview
  12.5.5 Bristol-Myers Squibb News
12.6 Effik
  12.6.1 Company Details
  12.6.2 Drugs for Vulvovaginal Candidiasis Product Offered
  12.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
  12.6.4 Main Business Overview
  12.6.5 Effik News
12.7 Teva
  12.7.1 Company Details
  12.7.2 Drugs for Vulvovaginal Candidiasis Product Offered
  12.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
  12.7.4 Main Business Overview
  12.7.5 Teva News
12.8 Sanofi
  12.8.1 Company Details
  12.8.2 Drugs for Vulvovaginal Candidiasis Product Offered
  12.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
  12.8.4 Main Business Overview
  12.8.5 Sanofi News
12.9 Cisen Pharmaceutical
  12.9.1 Company Details
  12.9.2 Drugs for Vulvovaginal Candidiasis Product Offered
  12.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
  12.9.4 Main Business Overview
  12.9.5 Cisen Pharmaceutical News
12.10 Kingyork Group
  12.10.1 Company Details
  12.10.2 Drugs for Vulvovaginal Candidiasis Product Offered
  12.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
  12.10.4 Main Business Overview
  12.10.5 Kingyork Group News

13 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Drugs for Vulvovaginal Candidiasis
Table Product Specifications of Drugs for Vulvovaginal Candidiasis
Figure Drugs for Vulvovaginal Candidiasis Report Years Considered
Figure Market Research Methodology
Figure Global Drugs for Vulvovaginal Candidiasis Consumption Growth Rate 2013-2023 (K Units)
Figure Global Drugs for Vulvovaginal Candidiasis Value Growth Rate 2013-2023 ($ Millions)
Table Drugs for Vulvovaginal Candidiasis Consumption CAGR by Region 2013-2023 ($ Millions)
Figure Product Picture of Cream
Table Major Players of Cream
Figure Product Picture of Pessary
Table Major Players of Pessary
Figure Product Picture of Other
Table Major Players of Other
Table Global Consumption Sales by Type (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type (2013-2018)
Figure Global Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2013-2018) ($ million)
Table Global Drugs for Vulvovaginal Candidiasis Value Market Share by Type (2013-2018) ($ Millions)
Figure Global Drugs for Vulvovaginal Candidiasis Value Market Share by Type (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Sale Price by Type (2013-2018)
Figure Drugs for Vulvovaginal Candidiasis Consumed in Hospital & Clinic
Figure Global Drugs for Vulvovaginal Candidiasis Market: Hospital & Clinic (2013-2018) (K Units)
Figure Global Drugs for Vulvovaginal Candidiasis Market: Hospital & Clinic (2013-2018) ($ Millions)
Figure Global Hospital & Clinic YoY Growth ($ Millions)
Figure Drugs for Vulvovaginal Candidiasis Consumed in Pharmacy
Figure Global Drugs for Vulvovaginal Candidiasis Market: Pharmacy (2013-2018) (K Units)
Figure Global Drugs for Vulvovaginal Candidiasis Market: Pharmacy (2013-2018) ($ Millions)
Figure Global Pharmacy YoY Growth ($ Millions)
Table Global Consumption Sales by Application (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application (2013-2018)
Figure Global Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Value by Application (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Value Market Share by Application (2013-2018)
Figure Global Drugs for Vulvovaginal Candidiasis Value Market Share by Application (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Sale Price by Application (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Sales by Players (2016-2018) (K Units)
Table Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Players (2016-2018)
Figure Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Players in 2016
Figure Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Players in 2017
Table Global Drugs for Vulvovaginal Candidiasis Revenue by Players (2016-2018) ($ Millions)
Table Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Players (2016-2018)
Figure Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Players in 2016
Figure Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Players in 2017
Table Global Drugs for Vulvovaginal Candidiasis Sale Price by Players (2016-2018)
Figure Global Drugs for Vulvovaginal Candidiasis Sale Price by Players in 2017
Table Global Drugs for Vulvovaginal Candidiasis Manufacturing Base Distribution and Sales Area by Players
Table Players Drugs for Vulvovaginal Candidiasis Products Offered
Table Drugs for Vulvovaginal Candidiasis Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
Table Global Drugs for Vulvovaginal Candidiasis Consumption by Regions 2013-2018 (K Units)
Table Global Drugs for Vulvovaginal Candidiasis Consumption Market Share by Regions 2013-2018
Figure Global Drugs for Vulvovaginal Candidiasis Consumption Market Share by Regions 2013-2018
Table Global Drugs for Vulvovaginal Candidiasis Value by Regions 2013-2018 ($ Millions)
Table Global Drugs for Vulvovaginal Candidiasis Value Market Share by Regions 2013-2018
Figure Global Drugs for Vulvovaginal Candidiasis Value Market Share by Regions 2013-2018
Figure Americas Drugs for Vulvovaginal Candidiasis Consumption 2013-2018 (K Units)
Figure Americas Drugs for Vulvovaginal Candidiasis Value 2013-2018 ($ Millions)
Figure APAC Drugs for Vulvovaginal Candidiasis Consumption 2013-2018 (K Units)
Figure APAC Drugs for Vulvovaginal Candidiasis Value 2013-2018 ($ Millions)
Figure Europe Drugs for Vulvovaginal Candidiasis Consumption 2013-2018 (K Units)
Figure Europe Drugs for Vulvovaginal Candidiasis Value 2013-2018 ($ Millions)
Figure Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption 2013-2018 (K Units)
Figure Middle East & Africa Drugs for Vulvovaginal Candidiasis Value 2013-2018 ($ Millions)
Table Americas Drugs for Vulvovaginal Candidiasis Consumption by Countries (2013-2018) (K Units)
Table Americas Drugs for Vulvovaginal Candidiasis Consumption Market Share by Countries (2013-2018)
Figure Americas Drugs for Vulvovaginal Candidiasis Consumption Market Share by Countries in 2017
Table Americas Drugs for Vulvovaginal Candidiasis Value by Countries (2013-2018) ($ Millions)
Table Americas Drugs for Vulvovaginal Candidiasis Value Market Share by Countries (2013-2018)
Figure Americas Drugs for Vulvovaginal Candidiasis Value Market Share by Countries in 2017
Table Americas Drugs for Vulvovaginal Candidiasis Consumption by Type (2013-2018) (K Units)
Table Americas Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type (2013-2018)
Figure Americas Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type in 2017
Table Americas Drugs for Vulvovaginal Candidiasis Consumption by Application (2013-2018) (K Units)
Table Americas Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application (2013-2018)
Figure Americas Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application in 2017
Figure United States Drugs for Vulvovaginal Candidiasis Consumption Growth 2013-2018 (K Units)
Figure United States Drugs for Vulvovaginal Candidiasis Value Growth 2013-2018 ($ Millions)
Figure Canada Drugs for Vulvovaginal Candidiasis Consumption Growth 2013-2018 (K Units)
Figure Canada Drugs for Vulvovaginal Candidiasis Value Growth 2013-2018 ($ Millions)
Figure Mexico Drugs for Vulvovaginal Candidiasis Consumption Growth 2013-2018 (K Units)
Figure Mexico Drugs for Vulvovaginal Candidiasis Value Growth 2013-2018 ($ Millions)
Table APAC Drugs for Vulvovaginal Candidiasis Consumption by Countries (2013-2018) (K Units)
Table APAC Drugs for Vulvovaginal Candidiasis Consumption Market Share by Countries (2013-2018)
Figure APAC Drugs for Vulvovaginal Candidiasis Consumption Market Share by Countries in 2017
Table APAC Drugs for Vulvovaginal Candidiasis Value by Countries (2013-2018) ($ Millions)
Table APAC Drugs for Vulvovaginal Candidiasis Value Market Share by Countries (2013-2018)
Figure APAC Drugs for Vulvovaginal Candidiasis Value Market Share by Countries in 2017
Table APAC Drugs for Vulvovaginal Candidiasis Consumption by Type (2013-2018) (K Units)
Table APAC Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type (2013-2018)
Figure APAC Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type in 2017
Table APAC Drugs for Vulvovaginal Candidiasis Consumption by Application (2013-2018) (K Units)
Table APAC Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application (2013-2018)
Figure APAC Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application in 2017
Figure China Drugs for Vulvovaginal Candidiasis Consumption Growth 2013-2018 (K Units)
Figure China Drugs for Vulvovaginal Candidiasis Value Growth 2013-2018 ($ Millions)
Figure Japan Drugs for Vulvovaginal Candidiasis Consumption Growth 2013-2018 (K Units)
Figure Japan Drugs for Vulvovaginal Candidiasis Value Growth 2013-2018 ($ Millions)
Figure Korea Drugs for Vulvovaginal Candidiasis Consumption Growth 2013-2018 (K Units)
Figure Korea Drugs for Vulvovaginal Candidiasis Value Growth 2013-2018 ($ Millions)
Figure Southeast Asia Drugs for Vulvovaginal Candidiasis Consumption Growth 2013-2018 (K Units)
Figure Southeast Asia Drugs for Vulvovaginal Candidiasis Value Growth 2013-2018 ($ Millions)
Figure India Drugs for Vulvovaginal Candidiasis Consumption Growth 2013-2018 (K Units)
Figure India Drugs for Vulvovaginal Candidiasis Value Growth 2013-2018 ($ Millions)
Figure Australia Drugs for Vulvovaginal Candidiasis Consumption Growth 2013-2018 (K Units)
Figure Australia Drugs for Vulvovaginal Candidiasis Value Growth 2013-2018 ($ Millions)
Table Europe Drugs for Vulvovaginal Candidiasis Consumption by Countries (2013-2018) (K Units)
Table Europe Drugs for Vulvovaginal Candidiasis Consumption Market Share by Countries (2013-2018)
Figure Europe Drugs for Vulvovaginal Candidiasis Consumption Market Share by Countries in 2017
Table Europe Drugs for Vulvovaginal Candidiasis Value by Countries (2013-2018) ($ Millions)
Table Europe Drugs for Vulvovaginal Candidiasis Value Market Share by Countries (2013-2018)
Figure Europe Drugs for Vulvovaginal Candidiasis Value Market Share by Countries in 2017
Table Europe Drugs for Vulvovaginal Candidiasis Consumption by Type (2013-2018) (K Units)
Table Europe Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type (2013-2018)
Figure Europe Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type in 2017
Table Europe Drugs for Vulvovaginal Candidiasis Consumption by Application (2013-2018) (K Units)
Table Europe Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application (2013-2018)
Figure Europe Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application in 2017
Figure Germany Drugs for Vulvovaginal Candidiasis Consumption Growth 2013-2018 (K Units)
Figure Germany Drugs for Vulvovaginal Candidiasis Value Growth 2013-2018 ($ Millions)
Figure France Drugs for Vulvovaginal Candidiasis Consumption Growth 2013-2018 (K Units)
Figure France Drugs for Vulvovaginal Candidiasis Value Growth 2013-2018 ($ Millions)
Figure UK Drugs for Vulvovaginal Candidiasis Consumption Growth 2013-2018 (K Units)
Figure UK Drugs for Vulvovaginal Candidiasis Value Growth 2013-2018 ($ Millions)
Figure Italy Drugs for Vulvovaginal Candidiasis Consumption Growth 2013-2018 (K Units)
Figure Italy Drugs for Vulvovaginal Candidiasis Value Growth 2013-2018 ($ Millions)
Figure Russia Drugs for Vulvovaginal Candidiasis Consumption Growth 2013-2018 (K Units)
Figure Russia Drugs for Vulvovaginal Candidiasis Value Growth 2013-2018 ($ Millions)
Figure Spain Drugs for Vulvovaginal Candidiasis Consumption Growth 2013-2018 (K Units)
Figure Spain Drugs for Vulvovaginal Candidiasis Value Growth 2013-2018 ($ Millions)
Table Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption by Countries (2013-2018) (K Units)
Table Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Market Share by Countries (2013-2018)
Figure Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Market Share by Countries in 2017
Table Middle East & Africa Drugs for Vulvovaginal Candidiasis Value by Countries (2013-2018) ($ Millions)
Table Middle East & Africa Drugs for Vulvovaginal Candidiasis Value Market Share by Countries (2013-2018)
Figure Middle East & Africa Drugs for Vulvovaginal Candidiasis Value Market Share by Countries in 2017
Table Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption by Type (2013-2018) (K Units)
Table Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type (2013-2018)
Figure Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type in 2017
Table Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption by Application (2013-2018) (K Units)
Table Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application (2013-2018)
Figure Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application in 2017
Figure Egypt Drugs for Vulvovaginal Candidiasis Consumption Growth 2013-2018 (K Units)
Figure Egypt Drugs for Vulvovaginal Candidiasis Value Growth 2013-2018 ($ Millions)
Figure South Africa Drugs for Vulvovaginal Candidiasis Consumption Growth 2013-2018 (K Units)
Figure South Africa Drugs for Vulvovaginal Candidiasis Value Growth 2013-2018 ($ Millions)
Figure Israel Drugs for Vulvovaginal Candidiasis Consumption Growth 2013-2018 (K Units)
Figure Israel Drugs for Vulvovaginal Candidiasis Value Growth 2013-2018 ($ Millions)
Figure Turkey Drugs for Vulvovaginal Candidiasis Consumption Growth 2013-2018 (K Units)
Figure Turkey Drugs for Vulvovaginal Candidiasis Value Growth 2013-2018 ($ Millions)
Figure GCC Countries Drugs for Vulvovaginal Candidiasis Consumption Growth 2013-2018 (K Units)
Figure GCC Countries Drugs for Vulvovaginal Candidiasis Value Growth 2013-2018 ($ Millions)
Table Drugs for Vulvovaginal Candidiasis Distributors List
Table Drugs for Vulvovaginal Candidiasis Customer List
Figure Global Drugs for Vulvovaginal Candidiasis Consumption Growth Rate Forecast (2018-2023) (K Units)
Figure Global Drugs for Vulvovaginal Candidiasis Value Growth Rate Forecast (2018-2023) ($ Millions)
Table Global Drugs for Vulvovaginal Candidiasis Consumption Forecast by Countries (2018-2023) (K Units)
Table Global Drugs for Vulvovaginal Candidiasis Consumption Market Forecast by Regions
Table Global Drugs for Vulvovaginal Candidiasis Value Forecast by Countries (2018-2023) ($ Millions)
Table Global Drugs for Vulvovaginal Candidiasis Value Market Share Forecast by Regions
Figure Americas Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure Americas Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure APAC Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure APAC Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure Europe Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure Europe Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure Middle East & Africa Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure United States Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure United States Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure Canada Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure Canada Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure Mexico Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure Mexico Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure Brazil Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure Brazil Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure China Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure China Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure Japan Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure Japan Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure Korea Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure Korea Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure Southeast Asia Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure Southeast Asia Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure India Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure India Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure Australia Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure Australia Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure Germany Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure Germany Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure France Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure France Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure UK Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure UK Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure Italy Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure Italy Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure Russia Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure Russia Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure Spain Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure Spain Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure Egypt Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure Egypt Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure South Africa Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure South Africa Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure Israel Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure Israel Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure Turkey Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure Turkey Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Figure GCC Countries Drugs for Vulvovaginal Candidiasis Consumption 2018-2023 (K Units)
Figure GCC Countries Drugs for Vulvovaginal Candidiasis Value 2018-2023 ($ Millions)
Table Global Drugs for Vulvovaginal Candidiasis Consumption Forecast by Type (2018-2023) (K Units)
Table Global Drugs for Vulvovaginal Candidiasis Consumption Market Share Forecast by Type (2018-2023)
Table Global Drugs for Vulvovaginal Candidiasis Value Forecast by Type (2018-2023) ($ Millions)
Table Global Drugs for Vulvovaginal Candidiasis Value Market Share Forecast by Type (2018-2023)
Table Global Drugs for Vulvovaginal Candidiasis Consumption Forecast by Application (2018-2023) (K Units)
Table Global Drugs for Vulvovaginal Candidiasis Consumption Market Share Forecast by Application (2018-2023)
Table Global Drugs for Vulvovaginal Candidiasis Value Forecast by Application (2018-2023) ($ Millions)
Table Global Drugs for Vulvovaginal Candidiasis Value Market Share Forecast by Application (2018-2023)
Table Bayer Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Bayer Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Bayer Drugs for Vulvovaginal Candidiasis Market Share (2016-2018)
Table Perrigo Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Perrigo Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Perrigo Drugs for Vulvovaginal Candidiasis Market Share (2016-2018)
Table J & J Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table J & J Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
Figure J & J Drugs for Vulvovaginal Candidiasis Market Share (2016-2018)
Table Pfizer Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Pfizer Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Pfizer Drugs for Vulvovaginal Candidiasis Market Share (2016-2018)
Table Bristol-Myers Squibb Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Market Share (2016-2018)
Table Effik Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Effik Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Effik Drugs for Vulvovaginal Candidiasis Market Share (2016-2018)
Table Teva Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Teva Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Teva Drugs for Vulvovaginal Candidiasis Market Share (2016-2018)
Table Sanofi Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Sanofi Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Sanofi Drugs for Vulvovaginal Candidiasis Market Share (2016-2018)
Table Cisen Pharmaceutical Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Market Share (2016-2018)
Table Kingyork Group Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Kingyork Group Drugs for Vulvovaginal Candidiasis Market Share (2016-2018)